Navigation Links
UCSF receives $112 million to help translate science into cures

A UCSF institute aimed at accelerating the pace of translating science into real-life solutions for patients has received $112 million from the National Institutes of Health to expand its work over the next five years.

The UCSF Clinical and Translational Science Institute (CTSI) is among 10 institutes nationwide to receive the renewed funding, in recognition of their successes during the first five years of the NIH's Clinical and Translational Science Awards program.

Together, the institutes represent a $498 million renewed commitment on NIH's part to expedite translational research nationwide. UCSF received the largest of the renewal grants and remains the country's second-largest clinical and translational science institute.

The other institutions include Columbia University Medical Center, Mayo Clinic, Oregon Health & Sciences University, Rockefeller University, UC Davis, University of Pennsylvania, University of Pittsburgh, University of Rochester, and Yale University.

"These institutes were the pioneers in this program and are to be commended for the work they have done in bridging the traditional divides between laboratory research and medical practice," said Barbara Alving, MD, director of the NIH's National Center for Research Resources, which administers the CTSA program. "They were tasked with transforming the way their institutions coordinate research to make it more proactive and effective in producing real-world results, and in the process, they have served as innovative models nationwide."

NIH will release a progress report on the program in August, highlighting research that has emerged from UCSF and other institutes in the CTSA consortium.

Promoting Collaboration

The renewal awards validate the success of CTSI and its sister programs in creating a framework for scientists to move beyond the traditional silos of science to collaborate on promising research and find the training and resources to move those projects ahead.

The UCSF institute has focused on creating resources at all levels of that spectrum, from fundamental biological research to industry partnerships, clinical trials and clinical research. The renewed funding will expand and enhance those programs, while also supporting CTSI's efforts to take those advances one step further to ensure they reach the community.

"UCSF is known for both outstanding fundamental research and for the level of care it provides to patients who are in greatest need," said UCSF Chancellor Susan Desmond-Hellmann, MD, MPH. "CTSI is helping us create that 'secret sauce' to help connect these two communities and deliver the breakthroughs that patients need throughout the world."

The size of UCSF's renewal underscores its leadership role across the 60 institutes that have been created through the NIH program, as well as the value of CTSI projects that will be rolled out under the new funding.

Bridging the Gap

CTSI was among the first seven of these institutes nationwide and was the largest when it received its initial 2006 grant award, totaling more than $100 million. Since then, the institute has enabled UCSF to create an extensive network of training and support for researchers to help bridge the gaps between laboratory science, clinical care, and improvements in health.

"UCSF is an incredible place, with superb basic science and also groundbreaking clinical research and care," said UCSF neurologist and CTSI Director S. Claiborne "Clay" Johnston, MD, PhD. "The great collaborative spirit of UCSF has made bridging the gap between these two types of research very doable. It has been exciting to think through how we might best facilitate our great faculty and to see some early evidence of success."

Research acceleration happens in a variety of ways, including identifying and addressing challenges that affect successful clinical research, such as the failure to recruit study participants. In response CTSI developed the UCSF Participant Recruitment Service, which will begin a pilot program later this summer.

"One of the greatest challenges clinical investigators face is finding enough people to enroll in studies," said Bill Balke, MD, director of CTSI's Clinical Research Services. "This program, the first of its kind at UCSF, will give researchers the tools and support they need to find and enroll study participants."

Breaking down Obstacles

Another key obstacle is funding. CTSI has awarded $4.5 million in pilot awards over the past four years, distributed across UCSF's four professional schools Dentistry, Medicine, Nursing and Pharmacy and will continue to support early-stage, or T1, research through a newly launched program, known as the T1 Translational Catalyst Award. That program helps researchers understand where their research stands in terms of commercial viability and pairs them with teams of academic and industry consultants to resolve critical obstacles early in the research process.

The institute also has created a comprehensive Consultation Service, the busiest of its kind across the national consortium, which matches researchers to faculty who help them address study design, complex biostatistics and a range of specialized research needs.

Beyond expert advice and funds, CTSI's Clinical Research Services has helped advance clinical research at UCSF by providing integrated services at eight adult and pediatric sites across the San Francisco Bay Area, ranging from nursing staff to sample processing and participant recruitment. The service has supported more than 1,500 UCSF and affiliated doctors in applying research advances to clinical practice.

Among the future projects are opportunities for UCSF scientists to collaborate with UC Berkeley to capitalize on its complementary strengths in engineering and business. CTSI is also launching strategic initiatives, such as a program that leverages community partnerships and research at UCSF to achieve measurable improvements in health for the San Francisco Bay Area.

Over the next five years, the UCSF institute will capture and relay key statistics on return on investment (ROI) and other metrics of success to expand not only its programs, but its ability to share progress rigorously and transparently. The institute will also share the software and other programs it has developed with the national network of institutes.


Contact: Kristen Bole
University of California - San Francisco

Related medicine news :

1. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
2. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
3. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
4. Receives Award for Customer Trust
5. Corporate Wellness Firm Limeade Receives SAS 70 Type II Report
6. Oridion Receives Frost & Sullivan's 2010 Customer Value Enhancement Award
7. Special Olympics Georgia Receives Grant from The Home Depot Foundation
8. NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter
9. WuXi PharmaTech Receives AAALAC Accreditation for Suzhou Toxicology Facility
10. Verdan Receives Patent on Crystal Deodorant Spray
11. Thomas E. Mower Meets With Dalai Lama; Receives Prestigious Champion Award from Whole Child International
Post Your Comments:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: